



Department of Health Care Finance
441 Fourth Street NW
Main Street Conference Room 1028 (10th Floor)
Washington, DC 20001



**PHARMACY & THERAPEUTICS
COMMITTEE MEETING**

**December 6th, 2018
Time: 2:30 PM – 5:30 PM**

- 1) Call to Order Charlene Fairfax, RPh
- 2) Minutes of Previous Meeting Charlene Fairfax, RPh
- 3) Comments from Interested Parties* Gidey Amare, RPh, MS
- 4) Clinical Drug Class Reviews Zakia Al-Amin, PharmD, BCACP RPh
Ronald E. Kavanagh, BSP Pharm, PharmD, PhD, RPh

Angiotensin Modulator Combinations Angiotensin Modulators Antianginal Agents (Ranexa) Antibiotics, Topical Anticoagulants Antihypertensives, Sympatholytics Antipsoriatics, Oral Antipsoriatics, Topical Antiviral Agents, Oral (HSV & Influenza) Antiviral Agents, Topical Beta-Blockers Calcium Channel Blockers	Hepatitis B Agents Hepatitis C Agents HIV and AIDS Treatments Immunomodulators, Atopic Dermatitis Immunomodulators, Topical Lipotropics, Others Lipotropics, Statins Methotrexate Oncology Agents-Breast (<i>Tentative</i>) Platelet Aggregation Inhibitors Rosacea Agents, Topical
---	---
- 5) Executive Session (Committee Only)** Charlene Fairfax, RPh
MMA Representatives
- 6) Final Recommendations of Preferred Drugs*** MMA Representatives
- 7) Announcement of Next Scheduled P&T Committee Meeting Charlene Fairfax, RPh
Thursday March 7th, 2019
- 8) Final Comments and Adjournment Charlene Fairfax, RPh

***Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only**

**** Closed Session**

*****Open Session**